Tuhura Biosciences, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1995-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://tuhurabio.com
Clinical Trials
6
Active:1
Completed:2
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Early Phase 1
1 (20.0%)Phase 2
1 (20.0%)Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Advanced Or Metastatic Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT06947928
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)
Phase 1
Not yet recruiting
- Conditions
- Advanced Or Metastatic Merkel Cell Carcinoma
- Interventions
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT06940440
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
Phase 1
Completed
- Conditions
- Basal Cell CarcinomaCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT04925713
- Locations
- 🇺🇸
Moore Clinical Research, Brandon, Florida, United States
IFx-Hu2.0 Expanded Access Program
- Conditions
- Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Registration Number
- NCT04853602
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers
Phase 1
Active, not recruiting
- Conditions
- Non-Melanoma Skin CancersMerkel Cell CarcinomaCutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- TuHURA Biosciences, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04160065
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Prev
- 1
- 2
- Next
News
No news found